

PROMOTION RECOMMENDATION
UNIVERSITY OF MICHIGAN
MEDICAL SCHOOL
DEPARTMENT OF INTERNAL MEDICINE

Approved by the Regents

May 14, 2009

Vallerie V. McLaughlin, M.D., associate professor of internal medicine, with tenure, Department of Internal Medicine, Medical School, is recommended for promotion to professor of internal medicine, with tenure, Department of Internal Medicine, Medical School.

Academic Degrees:

M.D.	1989	Northwestern University
B.S.	1985	Northwestern University

Professional Record:

2006-present	Associate Professor of Internal Medicine, with tenure, University of Michigan
2003-2006	Associate Professor of Internal Medicine, without tenure, University of Michigan
2002-2003	Associate Professor of Medicine, Rush Medical College
1996-2002	Assistant Professor of Medicine, Rush Medical College
1995-1996	Instructor in Medicine, University of Illinois at Chicago

Summary of Evaluation:

Teaching: Dr. McLaughlin teaches students, house officers, and fellows on a daily basis, both on the inpatient cardiology service and in the outpatient pulmonary hypertension clinic. She gives resident conference on pulmonary hypertension on a yearly basis, and 2-3 morning reports annually. She speaks at CME events locally, nationally, and internationally on a regular basis and has given the lecture on Pulmonary Hypertension at the American College of Cardiology Board Review course for 12 consecutive years. She served as chair of the Pulmonary Hypertension Association Medical Education Sessions, a series that took place in six U.S. cities during the years 2006 and 2007. As chair of the Scientific Leadership, she is now spearheading a new medical education program which will include CME programs in 30 selected U.S. cities, preceptorships at five selected academic institutions, a web based educational program, and a patient education program in six cities. She also frequently teaches patients at support group meetings and patient conferences.

Research: Dr. McLaughlin's main research focus has been in the area of pulmonary arterial hypertension. Under her leadership, the University's pulmonary hypertension program has been a leading enroller in many randomized, controlled trials (RCTs). She has served on the steering committee of four RCTs and is currently the chair of the steering committee of the COMPASS-2 trial, the first ever morbidity and mortality trial in pulmonary hypertension. She has authored many papers on the effects of various therapies in pulmonary hypertension. She has mentored two University of Michigan residents on research projects since her arrival five years ago. Both of these residents presented this research at American Thoracic Society meetings. She has also mentored two cardiology

fellows, one of whom published a manuscript. She is the principal investigator of the Data Coordinating Center and the chair of the steering committee for the Pulmonary Hypertension Breakthrough Initiative, a unique initiative designed to harvest explanted lungs, from pulmonary hypertension patients who undergo lung transplantation, for basic scientific study. As chair of the steering committee, she leads nine transplant sites, five core centers, and three special project centers. This project, on which Dr. McLaughlin has 30% effort, is going into its third successful year. In the past two years she has also chaired two other major projects, the American College of Cardiology/American Heart Association Clinical Expert Consensus Document, and the 4th World Symposium on Pulmonary Hypertension which was held in February of 2008. The proceedings of that meeting will be published as a supplement to the *Journal of the American College of Cardiology*, in early 2009 with Dr. McLaughlin and Marc Humber contributing as editors. Dr. McLaughlin has served as a reviewer, editor, or guest editor for many professional journals.

Recent and Significant Publications:

McSwain CS, Benza R, Shapiro S, Hill N, Schilz R, Elliott CG, Zwicke DL, Oudiz RJ, Staszewski JP, Arneson CP, Wade M, Zaccardelli D, McLaughlin V: Dose proportionality of treprostinil sodium administered by continuous subcutaneous and intravenous infusion. *J Clin Pharmacol* 48(1):19-25, 2008.

Badesh DB, Abman SN, Simmoneau G, Rubin, LJ, McLaughlin VV: Medical therapy for pulmonary arterial hypertension: Updated ACCP evidence-based clinical practice guidelines. *Chest* 131:1917-28, 2007.

McLaughlin VV, Oudiz RJ, Adaani F, Tapson VF, Murali S, Channick RN, Badesch DB, Barst RJ, Hsu HH, Rubin LJ: Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. *Am J Respir Crit Care Med* 174(11):1257-63, 2006.

McLaughlin VV, McGoon MD: Pulmonary arterial hypertension. *Circ* 114(13):1417-31, 2006.

McLaughlin VV, Sitbon O, Badesch DB, Barst RJ, Black C, Rainisio M, Simmoneau G, Rubin LJ: Survival and safety of first-line bosentan therapy in patients with primary pulmonary hypertension. *Eur Respiratory J* 25(2):244-249, 2005.

Service: Dr. McLaughlin directs the Pulmonary Hypertension Program at the University of Michigan, which has become one of the leading centers for pulmonary hypertension in the country. Dr. McLaughlin brings prestige to the University by her involvement in numerous organizations, commonly in leadership positions. She previously served as chair of the AHA Women in Cardiology Committee, on the American College of Chest Physicians Pulmonary Arterial Hypertension Guidelines Panel, as the editor-in-chief of *Advances in Pulmonary Hypertension*, the official journal of the Pulmonary Hypertension Association, as the chair of the Pulmonary Hypertension Association Medical Education Series for two consecutive years, and as chair of the Clinical Program at the Fourth World Symposium on Pulmonary Hypertension. She currently serves on the ACC Scientific Program Committee, as the chair of the AHA/ACC Clinical Expert Consensus Document (which is currently

under peer review), as the chair of the Pulmonary Hypertension Scientific Leadership Council, and as a member of the board of trustees of the Pulmonary Hypertension Association.

Professional Work: The pulmonary hypertension program, directed by Dr. McLaughlin, provides highly specialized care to this very ill population of patients with a rare, in fact, orphan disease. New referrals to the Pulmonary Hypertension Program have more than quadrupled since she joined the faculty in 2003. She has personally developed an extensive outreach program, commonly giving lectures at hospitals and to practices around the State. Given the association of pulmonary hypertension with certain other disorders, she commonly interacts with other services including pulmonary and critical care, hepatology, hematology, and rheumatology. Active research collaboration currently exists with faculty from both the pulmonary and critical care and rheumatology divisions of Internal Medicine.

External Review:

Reviewer A: “Dr. McLaughlin is remarkably productive and has established herself as a thought leader in the field of clinical care for pulmonary hypertension....her strength is in education and clinical care. Her national leadership in these areas is unquestionable.”

Reviewer B: “...she is an outstanding clinician scientist who is internationally recognized in the field of pulmonary hypertension (PAH)....She has more than ten active clinical trials that are funded by a number of institutions including pharmaceutical companies focused on therapies for pulmonary hypertension....she has served on a number of institutional and national committees and has played a leadership role in the development of guidelines for the treatment of pulmonary hypertension.”

Reviewer C: “I would rank Dr. McLaughlin as one of the top investigators in the field of pulmonary hypertension in this country in terms of clinical expertise, trial design, and knowledge of the field....Dr. McLaughlin has developed one of the most prominent pulmonary hypertension programs in the country at the University of Michigan.”


Reviewer D: “Dr. McLaughlin is nationally and internationally recognized for her contributions to the field of pulmonary hypertension. I would place her in the top 10% of investigators in this field.”

Reviewer E: “Dr. McLaughlin has transformed...to a major force in the pulmonary hypertension community with independent funding and highly effective leadership. She is beautifully organized, exerts leadership evenly and with superb direction and she has shown high organizational capacity with the PAH Network that is extremely impressive....She has risen to the top echelon in the PAH community both nationally and internationally, and she will certainly work at that level for the rest of her career.”

Reviewer F: “Dr. McLaughlin has emerged as a wonderful leader who has made major contributions to the field of pulmonary hypertension....Her leadership has been manifest in many different ways and she seems to know intuitively when it is necessary to have consensus and when executive decisions may be necessary but even in terms of the latter she manages to always get buy-in.”

Summary of Recommendation:

Dr. McLaughlin is an outstanding candidate for promotion to professor. She has already become a leader extraordinaire within the faculty of the Division of Cardiovascular Medicine and the pulmonary hypertension community worldwide. Her compassionate care of patients coupled with pioneering research has thrust her into the upper echelon of faculty physicians. I am pleased to recommend Vallerie V. McLaughlin, M.D. for promotion to professor of internal medicine.



James O. Woolliscroft, M.D.

Dean

Lyle C. Roll Professor of Medicine

May 2009